Qube Research & Technologies (QRT)’s Rapport Therapeutics RAPP Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.9M	Buy	+86,296	New	+$3.73M	﹤0.01%	2119

Other funds holding RAPP

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $54.9B AUM 27.38% 1-Year Est. Return

Qube Research & Technologies (QRT)'s RAPP Position: Q3 2026 in Review

Qube Research & Technologies (QRT) opened a new position in Rapport Therapeutics (RAPP) in Q3 2026: 86,296 shares worth $2.9M. The stake represents ﹤0.01% of the portfolio and ranks #2119 among its holdings.

114 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

Qube Research & Technologies (QRT) held 86,296 shares of Rapport Therapeutics worth $2.9M as of Q3 2026.
Rapport Therapeutics was a new Qube Research & Technologies (QRT) position in Q3 2026.
Rapport Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q3 2026, its #2119 holding.
114 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2026, filed 13 Nov 2026.